TSX:ONC 0.78 CAD +0.04 +5.41% Volume: 67,380 November 21, 2014
NASDAQ:ONCY 0.69 USD +0.03 +5.2% Volume: 268,579 November 21, 2014

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

November 18, 2014 Media Advisory - Oncolytics Biotech® Inc. to Participate in the Stifel 2014 Healthcare Conference
November 06, 2014 Oncolytics Biotech® Inc. Announces Third Quarter 2014 Results
November 04, 2014 Oncolytics Biotech® Inc. Announces Receipt of Nasdaq Notice of Deficiency
Sign up to receive e-mail updates *